Search & Analyze

Glaxosmithkline Pharmaceuticals Ltd.

2,505.00−10.65 (−0.42%)

BSE · 30 Oct, 4:01 PM

: ₹42,072.84 Cr
: 39.39
: 1,795
: ₹2,528.85 - ₹2,480.00
: ₹3,121.10 - ₹2,088.00

Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) share price closed at ₹2,505.00 on the BSE on Friday, October 30, 2026, down by 0.42% from its of ₹2,515.65. In that session GLAXO reached a of 2,528.85 and of 2,480.00. The for the session was 2,497.53. The stands at 2,766.10 and is at 2,513.15. Looking at , the stock ended the session moving sideways.

Stock Overview

₹2,526.15

₹2,515.65

₹2,497.53

₹2,766.10

Price 9.44% below

₹2,513.15

Price 0.32% below

Key Fundamentals

: 42,072.84 Cr₹42.07 Thousand Crore
: 63.05
: 39.39
: 16.69
: 148.77
: 1,498.90 Cr₹1.50 Thousand Crore
: 2.30 %
Sector
Industry: Pharmaceuticals & Drugs
: 48.76
: 0.00

Industry Comparison

Ratio	Company	Sector
	39.39	44.77
	0.00	0.20
	16.69	4.61
	2.03	1.81
	2.30 %	0.11 %
Operating Margin	31.01 %	19.15 %

Sector figures are the median of 154 listed Healthcare companies.

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,778.25	38.91	4,26,661.74	0.90	1,995.07	-36.16%	16,198.71	11.88%	19.11
DIVI'S LAB. DIVISLAB	9,715.00	88.17	2,57,902.73	0.31	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,635.15	83.01	1,76,306.21	0.82	534.00	-9.64%	4,979.00	50.79%	19.27
LAURUSLABS LAURUSLABS	2,392.00	96.46	1,29,242.68	0.08	436.19	124.27%	2,206.37	33.44%	18.20
ZYDUSLIFE ZYDUSLIFE	1,244.00	27.50	1,24,089.48	0.08	990.20	-34.90%	8,017.00	21.96%	21.39
DR.REDDY'S DRREDDY	1,350.20	40.25	1,12,698.53	0.59	913.20	-31.69%	8,697.80	-1.48%	13.75
CIPLA LTD. CIPLA	1,380.00	38.48	1,11,488.55	0.94	851.51	-37.08%	7,403.93	-2.44%	16.00
Glaxosmithkline Pharmaceuticals Ltd. GLAXO	2,505.00	39.39	42,072.84	2.30	237.18	15.69%	938.44	16.55%	66.79

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	929.80	814.65	1,010.77	949.42	974.37	805.17	979.94	1,041.26	995.30	938.44
Expenses	672.54	584.11	689.06	657.50	641.18	553.97	644.21	669.92	644.37	642.94
	257.26	230.54	321.71	291.92	333.19	251.20	335.73	371.34	350.93	295.50
	27.67%	28.30%	31.83%	30.75%	34.20%	31.20%	34.26%	35.66%	35.26%	31.49%
	32.23	35.64	39.23	35.07	40.68	43.72	36.21	50.10	35.95	43.76
Interest	0.77	0.37	0.27	0.09	0.58	0.42	0.51	1.19	0.61	0.97
	18.10	16.41	16.86	18.80	14.72	15.52	17.43	20.32	13.17	15.84
	270.62	249.40	343.81	308.10	358.57	278.98	354.00	399.93	373.10	322.45
	28.14%	26.89%	26.56%	25.39%	26.69%	26.51%	27.26%	26.08%	25.53%	26.44%
	194.48	182.33	252.50	229.88	262.87	205.01	257.49	295.62	277.86	237.18
	11.48	10.76	14.90	13.57	15.52	12.10	15.20	17.45	16.40	14.00

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	3,594.34	3,568.12	3,784.62	4,122.91	4,222.33
	3,278.03	3,251.72	3,453.71	3,749.21	3,821.67
EXPENDITURE :
Increase/Decrease in Stock	15.57	68.96	-63.72	45.85	4.46
Raw Material Consumed	1,340.62	1,215.92	1,398.25	1,345.00	1,346.59
Power & Fuel Cost	27.83	29.60	29.64	30.18	30.36
Employee Cost	610.23	594.99	624.39	579.70	607.25
Other Manufacturing Expenses	120.14	99.05	113.61	114.26	101.49
General and Administration Expenses	144.08	189.33	190.50	194.14	163.38
Selling and Distribution Expenses	199.59	180.97	184.23	189.84	203.15
Miscellaneous Expenses	58.09	68.62	68.13	72.87	55.79
	2,516.15	2,447.44	2,545.02	2,571.85	2,512.47
Operating Profit (Excl OI)	761.88	804.29	908.69	1,177.36	1,309.20
	75.78	100.66	122.59	145.93	145.36
	837.65	904.95	1,031.28	1,323.29	1,454.56
Interest	2.00	1.81	1.80	1.31	2.73
PBDT	835.66	903.14	1,029.48	1,321.98	1,451.83
	68.19	65.77	69.68	66.79	66.44
Profit Before Taxation & Exceptional Items	767.47	837.37	959.80	1,255.19	1,385.39
Exceptional Income / Expenses	11.58	-0.97	-143.62	4.69	20.63
	779.05	836.40	816.19	1,259.88	1,406.01
Provision for Tax	398.28	228.76	226.23	332.30	370.03
	380.77	607.64	589.96	927.58	1,035.98
Extra items				0.00	0.00
Consolidated Net Profit	1,694.72	610.69	589.96	927.58	1,035.98
Profit Balance B/F	556.04	1,742.54	828.57	876.44	1,058.63
Appropriations	2,250.76	2,353.23	1,418.53	1,804.02	2,094.61
Equity Dividend %	900.00%	320.00%	320.00%	540.00%	570.00%
	100.04	36.05	34.83	54.76	61.15
Adjusted EPS	100.04	36.05	34.83	54.76	61.15

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	169.41	169.41	169.41	169.41	169.41
Share Warrants & Outstandings		-1.68	-9.01	-14.88	-15.71
Total Reserves	2,493.55	1,573.54	1,617.24	1,796.78	2,113.72
Reserve excluding Revaluation Reserve	2,493.55	1,573.54	1,617.24	1,796.78	2,113.72
Revaluation reserve	0.00
	2,662.96	1,741.27	1,777.64	1,951.31	2,267.42
Deferred Tax Assets / Liabilities	-113.15	-133.55	-146.31	-140.87	-133.85
Other Long Term Liabilities	9.68	4.14	6.57	2.49	17.27
Long Term Provisions	262.21	254.80	247.46	249.11	260.07
Total Non-Current Liabilities	158.75	125.40	107.72	110.73	143.50
Trade Payables	579.33	427.79	625.41	708.25	570.22
Other Current Liabilities	503.74	184.59	207.44	255.98	243.74
Short Term Provisions	615.36	713.99	692.10	940.93	965.14
Total Current Liabilities	1,698.43	1,326.37	1,524.95	1,905.15	1,779.10
Total Liabilities	4,520.13	3,193.04	3,410.31	3,967.20	4,190.02
Gross Block	591.65	633.68	663.27	666.70	716.18
Less: Accumulated Depreciation	262.20	304.79	342.91	383.83	436.10
	329.44	328.90	320.36	282.87	280.08
	30.50	20.31	13.93	14.32	32.93
Non Current Investments					0.87
Long Term Investment	0.00				0.87
Long Term Loans & Advances	445.49	347.40	275.44	258.89	269.04
Other Non Current Assets	5.45	1.10	1.24	0.45	0.26
Total Non-Current Assets	812.10	698.77	611.89	557.32	583.82
Currents Investments	365.59	518.29	813.22	1,118.25	1,390.96
Inventories	534.70	459.97	525.05	481.74	457.55
Sundry Debtors	205.24	192.38	222.06	292.55	273.11
Cash and Bank	2,484.51	1,155.93	1,063.22	1,403.52	1,391.02
Other Current Assets	89.49	155.48	150.19	87.40	57.01
Short Term Loans and Advances	28.40	12.22	24.68	26.44	36.54
Total Current Assets	3,707.92	2,494.26	2,798.42	3,409.88	3,606.20
Net Current Assets (Including Current Investments)	2,009.49	1,167.89	1,273.47	1,504.73	1,827.09
Total Assets	4,520.13	3,193.04	3,410.31	3,967.20	4,190.02
	354.78	353.87	387.33	456.22	515.18
Total Debt	0.00	0.00	0.00	0.00	0.00
	157.19	102.89	105.47	116.06	134.77
Adjusted Book Value	157.19	102.89	105.47	116.06	134.77

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	2,475.65	841.49	959.80	1,255.19	1,385.39
Adjustment	-1,636.48	-40.00	-45.13	-68.41	-65.25
Changes In working Capital	119.87	-45.75	61.02	184.83	-98.17
Cash Flow after changes in Working Capital	959.04	755.75	975.69	1,371.61	1,221.97
Cash Flow from Operating Activities	810.75	484.23	582.02	1,289.90	903.30
Cash Flow from Investing Activities	-405.51	807.85	8.71	-45.80	396.98
Cash Flow from Financing Activitie	-524.24	-1,543.32	-561.50	-769.42	-737.08
Net Cash Inflow / Outflow	-119.00	-251.25	29.23	474.68	563.20
Opening Cash & Cash Equivalents	405.19	286.19	34.94	64.17	538.85
Closing Cash & Cash Equivalent	286.19	34.94	64.17	538.85	1,102.05

Ratios

Valuation

39.39

16.69

27.14

10.64

63.05

148.77

Profitability

48.76

66.79

25.40

31.01

24.54

Leverage & Liquidity

0.00

2.03

515.59

Returns

2.30

1.04

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26	Sep '26
	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00	75.00
	11.52	11.69	11.80	12.31	12.59	12.55	12.34	12.30	12.59	13.23
	13.48	13.30	13.19	12.69	12.41	12.45	12.66	12.70	12.41	11.77
	25.00	25.00	25.00	25.00	25.00	25.00	25.00	25.00	25.00	25.00
No. of Shareholders	1,18,515	1,19,228	1,19,625	1,21,885	1,23,629	1,22,904	1,22,460	1,21,763	1,26,087	1,19,337

Mutual Funds Invested(142)

Based on each fund's latest monthly portfolio · Sep 2026

A total of 72 active funds hold 5.88% in Glaxosmithkline Pharmaceuticals Ltd., contributing to ₹2.76K Cr of holdings

Fund				As of
SB SBI Midcap Fund - Growth - Direct PlanMid Cap Fund	326.78	1.40	11,80,000	Sep '26
KO Kotak Large & Mid Cap Fund - Growth - Direct PlanLarge & Mid Cap	304.62	1.00	11,00,000	Sep '26
NI Nippon India Pharma Fund - Growth - Direct PlanPharma & Health Care	285.09	3.11	10,29,460	Sep '26
QU Quant Mid Cap Fund - Growth - Direct PlanMid Cap Fund	246.33	3.22	8,89,486	Sep '26
NI Nippon India Growth Mid Cap Fund - Growth Option - Direct PlanMid Cap Fund	154.80	0.31	5,59,000	Sep '26
SB SBI Dividend Yield Fund - Growth - Direct PlanEquity - Dividend Yield Fund	124.62	1.55	4,50,000	Sep '26
ID Bandhan Large & Mid Cap Fund - Growth - Direct PlanLarge & Mid Cap	96.33	0.47	3,47,860	Sep '26
BF Bajaj Finserv Flexi Cap Fund - Growth - Direct PlanFlexi Cap Fund	92.97	1.09	3,35,705	Sep '26
ID Bandhan ELSS - Tax Saver Fund - Growth - Direct PlanEquity - ELSS - Tax Saver Fund	76.16	1.15	2,75,000	Sep '26
TA Tata Aggressive Hybrid Fund - Growth - Direct PlanHybrid - Aggressive Hybrid Fund	69.23	1.74	2,50,000	Sep '26

Corporate Actions

Showing: All

Date	Type	Details	Ex-Date	Record Date
2026-10-13	Board Meeting	Quarterly Results
2026-07-21	Board Meeting	Quarterly Results
2026-05-13	Ex Dividend	Rs.57.0000 per share(570%)Final Dividend	2026-05-29	2026-05-29

Insider Trading

Date	Person	Category	Transaction Type	Shares	Value (₹)

No insider trading data available.

Sector Overview

HealthcarePharmaceuticals & Drugs

Glaxosmithkline Pharmaceuticals Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

12 members across the board and senior leadership

R S Karnad

Chairperson

₹33.00 L

Mar '26

Bhushan Akshikar

Managing Director

₹8.27 Cr

Mar '26

Renu Sud Karnad

Chairperson

₹33.00 L

Mar '25

Manu Anand

Non Executive Independent Director

₹28.00 L

Mar '26

Ronojit Biswas

Whole Time Director & Chief Financial Officer

—

S Maheshwari

Non Executive Independent Director

₹24.50 L

Mar '26

P R Somasundaram

Non Executive Independent Director

₹27.00 L

Mar '26

Sunita Maheshwari

Non Executive Independent Director

₹24.00 L

Mar '25

Anup Wadhawan

Non Executive Independent Director

₹25.50 L

Mar '26

S Williams

Non Executive Director

—

Ajay Nadkarni

Company Secretary & Compliance Officer, Vice President – Administration, Real Estate

—

Karine JF Natland

Non-Execuive Director

—

GLAXO Latest News

News

6 of 6 articles

EQUITY2 Sept 2026 · 17:07

GlaxoSmithKline Pharmaceuticals informs about press release

EQUITY21 Jul 2026 · 12:57

GlaxoSmithKline Pharmaceuticals informs about board meeting

EQUITY25 Jun 2026 · 14:43

GlaxoSmithKline Pharmaceuticals informs about disclosure

EQUITY8 Jun 2026 · 12:21

GlaxoSmithKline Pharmaceuticals informs about letter for weblink for annual report

EQUITY26 May 2026 · 13:01

GlaxoSmithKline Pharmaceuticals informs about secretarial compliance report

EQUITY13 May 2026 · 14:47

Glaxosmithkline Phar reports Profit after tax of Rs 2749.40 Mln, in the March 2026 quarter

Glaxosmithkline Pharmaceuticals Ltd.

Stock Overview

Price chart

Peer Comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Valuation

Profitability

Leverage & Liquidity

Returns

Shareholding Pattern

Mutual Funds Invested(142)

Corporate Actions

Insider Trading

Sector Overview

Company Profile

Key Management

GLAXO Latest News

News